The estimated Net Worth of Mark S Cohen is at least 3.69 百万$ dollars as of 18 September 2015. Mark Cohen owns over 1,055,600 units of Akari Therapeutics Plc stock worth over 3,693,439$ and over the last 9 years Mark sold AKTX stock worth over 0$.
Mark has made over 1 trades of the Akari Therapeutics Plc stock since 2015, according to the Form 4 filled with the SEC. Most recently Mark bought 1,055,600 units of AKTX stock worth 200,564$ on 18 September 2015.
The largest trade Mark's ever made was buying 1,055,600 units of Akari Therapeutics Plc stock on 18 September 2015 worth over 200,564$. On average, Mark trades about 351,867 units every 0 days since 2015. As of 18 September 2015 Mark still owns at least 1,055,600 units of Akari Therapeutics Plc stock.
You can see the complete history of Mark Cohen stock trades at the bottom of the page.
Mark's mailing address filed with the SEC is 8, 24 W 40th St, New York, NY 10018, USA.
Over the last 9 years, insiders at Akari Therapeutics Plc have traded over 0$ worth of Akari Therapeutics Plc stock and bought 1,055,600 units worth 200,564$ . The most active insiders traders include Mark S Cohen、Wendy F Dicicco、Dov Elefant. On average, Akari Therapeutics Plc executives and independent directors trade stock every 0 days with the average trade being worth of 3,693,439$. The most recent stock trade was executed by Mark S Cohen on 18 September 2015, trading 1,055,600 units of AKTX stock currently worth 200,564$.
akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. akari’s lead drug, coversin, a second-generation and potentially best-in-class complement inhibitor, acts on complement component-c5, preventing release of c5a and formation of c5b – 9 (also known as the membrane attack complex or mac). coversin is a recombinant small protein (16,740 da) derived from a native protein discovered in the saliva of the ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.
Akari Therapeutics Plc executives and other stock owners filed with the SEC include: